규제 승인 상태: 파이프라인 화합물, 개발 중, 아직 승인되지 않음
IUPAC Name: N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide;methylsulfinylmethane
EC Number: 629-898-8
Molecular Weight: 693.5
Chemical Formula: C₂₈H₂₉FIN₅O₅S
CAS Number: 1187431-43-1
용도: MEK 억제제 병용요법용 종양학 원료의약품(BRAF 변이암, 신경교종)
제형 유형: DMSO 용매화물(다형체)
원산지: 유럽(EU 기반 API 제조업체)
Status: Pipeline
Development phase: Under development
Therapeutic cat.: Oncology
Polymorphic form: DMSO solvate
OEB No.: 5
Samples: Q4 2024

기타 정보

추가 설명:

Established in 1935 and based in the Greater Poland Voivodeship, Polpharma is a manufacturer and service provider of active pharmaceutical ingredients spanning prophylactic biological products, central nervous system drugs, cardiovascular system drugs and related APIs, offering CDMO contract manufacturing to markets across North America, Latin America, Western and Eastern Europe, Australasia, Asia, the Middle East and Africa. Drawing on 75 years of experience in the API business, Polpharma API covers the full value chain from R&D through production and supply chain management to project management, operating from a European base with R&D and two manufacturing plants, and specializes in high-potency APIs (OEB 5&6), high-potency ADC payloads, advanced linker technologies, customizable ADC development solutions, cryogenic reactions and oligonucleotides. The company is recognized for international certification, an experienced R&D team, strong reputation, high-quality service and a genuinely global market presence.